clevercast
{"PLE04":{"id":"WdekGw","strictid":"PLE04","name":"PLE04","description":"","account_id":"2bK6rw","ts":0},"PLE05":{"id":"W9mpyj","strictid":"PLE05","name":"PLE05 Closing Ceremony + Concert","description":"","account_id":"2bK6rw","ts":1638855000},"SAT09":{"id":"VvyakX","strictid":"SAT09","name":"SAT09","description":"","account_id":"2bK6rw","ts":1638889200},"SPI07":{"id":"WwGDRw","strictid":"SPI07","name":"SPI07","description":"","account_id":"2bK6rw","ts":1638874920},"SCS14":{"id":"2avEmE","strictid":"SCS14","name":"SCS14","description":"","account_id":"2bK6rw","ts":1638874920},"SCS13":{"id":"A6nmKN","strictid":"SCS13","name":"SCS13","description":"","account_id":"2bK6rw","ts":1638874920},"KEY09":{"id":"Wlqkxg","strictid":"KEY09","name":"KEY09","description":"","account_id":"2bK6rw","ts":1638874920},"KEY06":{"id":"AGZbol","strictid":"KEY06","name":"KEY06","description":"","account_id":"2bK6rw","ts":1638873120},"KEY01":{"id":"AR1vr7","strictid":"KEY01","name":"KEY01","description":"","account_id":"2bK6rw","ts":1638871320},"PLE03":{"id":"VyOE09","strictid":"PLE03","name":"PLE03","description":"","account_id":"2bK6rw","ts":1638867600},"WEB05":{"id":"AKYxLw","strictid":"WEB05","name":"WEB05","description":"","account_id":"2bK6rw","ts":1638824520},"WEB04":{"id":"V316Xb","strictid":"WEB04","name":"WEB04","description":"","account_id":"2bK6rw","ts":1638817320},"KEY05":{"id":"WNKJlG","strictid":"KEY05","name":"KEY05","description":"","account_id":"2bK6rw","ts":1638811920},"SPI06":{"id":"VBXxdo","strictid":"SPI06","name":"SPI06","description":"","account_id":"2bK6rw","ts":0},"SCS12":{"id":"VYeD58","strictid":"SCS12","name":"SCS12","description":"","account_id":"2bK6rw","ts":1638810120},"SCS10":{"id":"VDrPkz","strictid":"SCS10","name":"SCS10","description":"","account_id":"2bK6rw","ts":1638810120},"KEY03":{"id":"W9mpEj","strictid":"KEY03","name":"KEY03","description":"","account_id":"2bK6rw","ts":1638810120},"SAT08":{"id":"VvyaNX","strictid":"SAT08","name":"SAT08","description":"","account_id":"2bK6rw","ts":0},"SAT07":{"id":"WwGD3w","strictid":"SAT07","name":"SAT07","description":"","account_id":"2bK6rw","ts":0},"SPI05":{"id":"VznBKn","strictid":"SPI05","name":"SPI05","description":"","account_id":"2bK6rw","ts":1638788520},"SCS11":{"id":"ApYQ5M","strictid":"SCS11","name":"SCS11","description":"","account_id":"2bK6rw","ts":1638788520},"SCS09":{"id":"2MnrZe","strictid":"SCS09","name":"SCS09","description":"","account_id":"2bK6rw","ts":1638788520},"SPI04":{"id":"Wlqkpg","strictid":"SPI04","name":"SPI04","description":"","account_id":"2bK6rw","ts":1638781320},"SCS08":{"id":"ALoQw5","strictid":"SCS08","name":"SCS08","description":"","account_id":"2bK6rw","ts":1638781320},"SCS07":{"id":"AGZbgl","strictid":"SCS07","name":"SCS07","description":"","account_id":"2bK6rw","ts":1638781320},"WEB03":{"id":"WokLe9","strictid":"WEB03","name":"WEB03","description":"","account_id":"2bK6rw","ts":1638738120},"SAT04":{"id":"Ak6yrj","strictid":"SAT04","name":"SAT04","description":"","account_id":"2bK6rw","ts":0},"SAT06":{"id":"WdekLm","strictid":"SAT06","name":"SAT06","description":"","account_id":"2bK6rw","ts":0},"KEY08":{"id":"WNKJwG","strictid":"KEY08","name":"KEY08","description":"","account_id":"2bK6rw","ts":1638716520},"KEY10":{"id":"2bzB4G","strictid":"KEY10","name":"KEY10","description":"","account_id":"2bK6rw","ts":0},"SCS04":{"id":"VPxn5l","strictid":"SCS04","name":"SCS04","description":"","account_id":"2bK6rw","ts":1638716520},"SCS03":{"id":"WdekLP","strictid":"SCS03","name":"SCS03","description":"","account_id":"2bK6rw","ts":1638716520},"SPI02":{"id":"21a6D6","strictid":"SPI02","name":"SPI02","description":"Societal impact of influenza and COVID-19","account_id":"2bK6rw","ts":1638702120},"KEY02":{"id":"VznBQJ","strictid":"KEY02","name":"KEY02","description":"","account_id":"2bK6rw","ts":1638702000},"SCS06":{"id":"ApYQJq","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"2bK6rw","ts":1638702120},"SPI01":{"id":"AZzDlk","strictid":"SPI01","name":"SPI01","description":"Why influenza is a priority for policy makers","account_id":"2bK6rw","ts":1638694920},"SCS02":{"id":"Wj0kJZ","strictid":"SCS02","name":"SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"2bK6rw","ts":1638694920},"SCS01":{"id":"24amLe","strictid":"SCS01","name":"SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"2bK6rw","ts":1638694920},"WEB02":{"id":"Ak6yJr","strictid":"WEB02","name":"WEB02","description":"Childhood Influenza vaccination and treatment in a COVID-19 era","account_id":"2bK6rw","ts":1638651720},"OPN01":{"id":"WqYk9o","strictid":"OPN01","name":"OPN01","description":"Opening Ceremony\n","account_id":"2bK6rw","ts":1638637200},"KEY04":{"id":"27y68N","strictid":"KEY04","name":"KEY04","description":"COVID coagulopathy in comparison to influenza and pneumococci sepsis","account_id":"2bK6rw","ts":1638694920},"PER01":{"id":"2bzBJX","strictid":"PER01","name":"Permanent Livestream","description":"","account_id":"2bK6rw","ts":0},"SAT03":{"id":"VBXxaB","strictid":"SAT03","name":"SAT03","description":"","account_id":"2bK6rw","ts":1638630000},"SAT02":{"id":"VYeDlQ","strictid":"SAT02","name":"SAT02","description":"INFLUENZA AND COVID-19 Burden of Disease and Prospects for Vaccination","account_id":"2bK6rw","ts":1638622800},"SAT01":{"id":"VBXxPX","strictid":"SAT01","name":"SAT01 ","description":"Post-COVID lockdown era: what are we facing?","account_id":"2bK6rw","ts":1638615600},"WEB01":{"id":"VYeD8w","strictid":"WEB01","name":"WEB01","description":"Vaccination in a COVID-19 era","account_id":"2bK6rw","ts":1638644520},"SAT05":{"id":"ApYQNa","strictid":"SAT05","name":"SAT05","description":"Will be streamed by Roche, not from studio Antwerp, BE","account_id":"2bK6rw","ts":1638709200}}
clevercast items
{"LAN01":{"id":"WEBElL","strictid":"LAN01","name":"Lange testtrailer","description":"","account_id":"2bK6rw","chapters":[]},"TES01":{"id":"W9Jpob","strictid":"TES01","name":"Testtrailer","description":"Test trailer for scheduling Pseudo Live Events","account_id":"2bK6rw","chapters":[]}}
Sun 5 Dec
Sunday
5
December

Sunday 5 December, 10:00 - 10:30 CET

Keynote lecture: COVID coagulopathy in comparison to influenza and pneumococci sepsisKEY04

Time:

Sunday 5 December, 10:00 - 10:30 CET

Track:

Keynote lectures


Speaker:
Marco Goeijenbier, Erasmus MC

Sunday 5 December, 12:00 - 13:45 CET

Keynote lectures on Science based management of epidemics and pandemicsKEY02

Live
Time:

Sunday 5 December, 12:00 - 13:45 CET

Tracks:

Scientific Programme, Keynote lectures


Speaker:
Ab Osterhaus, TiHo, Hannover


Programme:
  1. Household transmission studies

    Ben Cowling, The University of Hong Kong, Hong Kong S.A.R.
  2. Science based management of epidemics and pandemics

    Peter Openshaw, Imperial College London, United Kingdom

Sunday 5 December, 16:00 - 16:30 CET

Keynote lecture: Regulatory approvals in the USKEY08

Time:

Sunday 5 December, 16:00 - 16:30 CET

Track:

Keynote lectures


Speaker:
Arnold Monto, University of Michigan

Sunday 5 December, 16:30 - 17:00 CET

Keynote lecture: Next generation COVID-19 vaccinesKEY10

Time:

Sunday 5 December, 16:30 - 17:00 CET

Track:

Keynote lectures


Speaker:
Florian Krammer, Icahn School of Medicine at Mount Sinai
Mon 6 Dec
Monday
6
December

Monday 6 December, 18:00 - 18:30 CET

Keynote lecture: Viral and host factors in the transmission of influenza and Covid-19KEY03

Time:

Monday 6 December, 18:00 - 18:30 CET

Track:

Keynote lectures


Speaker:
Wendy Barclay, Imperial College London

Monday 6 December, 18:30 - 19:00 CET

Keynote lecture: Antibodies against SARS-CoV-2: A Global CollaborationKEY05

Time:

Monday 6 December, 18:30 - 19:00 CET

Track:

Keynote lectures


Speaker:
Erica Ollmann Saphire, La Jolla Institute
Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 11:00 - 11:30 CET

Keynote lecture: Likelihood of transmission of baloxavir-resistant influenza viruses from baloxavir-treated index patients to untreated household contacts in the BLOCKSTONE studyKEY01

Time:

Tuesday 7 December, 11:00 - 11:30 CET

Track:

Keynote lectures


Speaker:
Aeron Hurt, Roche

Tuesday 7 December, 11:30 - 12:00 CET

Keynote lecture: Human challenge studies: limitations and strenghtsKEY06

Time:

Tuesday 7 December, 11:30 - 12:00 CET

Track:

Keynote lectures


Speaker:
Christopher Chiu, Imperial College London

Tuesday 7 December, 12:00 - 12:30 CET

Keynote lecture: Vaccine development and ensuring equitable acces to those most in needKEY09

Time:

Tuesday 7 December, 12:00 - 12:30 CET

Track:

Keynote lectures


Speaker:
Melanie Saville, CEPI
  FILTER